SCHEMBL1010020

SCHEMBL1010020

CC(C)(Oc1ccccc1CNCC(Oc1ccccc1)c1nc2ccccc2o1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.39
PPARG P37231 7/20 0.39
PPARD Q03181 3/20 0.39
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
PTPN1 P18031 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MGLL Q99685 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35
POLB P06746 1/20 0.35
P2RY14 Q15391 1/20 0.35
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012141 0.91 PPARA (0.40) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1010640 0.90 PPARG (0.40) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1011109 0.86 PPARA (0.50) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1012350 0.86 MAPT (0.39) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1009837 0.85 PPARA (0.52) PPARAPPARGPPARDP2RY14
SCHEMBL1010703 0.84 PPARG (0.39) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1009671 0.81 PPARA (0.47) PPARAPPARGPPARDMAPTPTPN1
SCHEMBL1009876 0.81 ADRB3 (0.56) PPARAPPARGPPARDMAPTALDH1A1
SCHEMBL1009987 0.81 PPARA (0.48) PPARAPPARGPPARDMAPTALDH1A1
SCHEMBL1009685 0.80 PPARG (0.54) PPARAPPARGPPARDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.